Amneal Pharmaceuticals, Inc. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; unaudited. Comparisons are with Q1 2020 unless otherwise noted. Amounts below are in U.S. dollars; financial figures are rounded to millions.
Business context and results
Amneal develops, manufactures, markets and distributes generic and branded pharmaceuticals. Its reportable segments are Generics, Specialty and AvKARE. The company reported nearly flat consolidated revenue, with lower Generics sales offset by growth in Specialty and AvKARE.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 | Change / context |
|---|---|---|---|
| Net revenue | $493.1m | $498.5m | Down 1% |
| Gross profit | $191.6m | $183.5m | Gross margin 38.8%, up from 36.8% |
| Operating income | $45.9m | $57.8m | Operating margin 9.3%, down from 11.6% |
| Net income | $14.5m | $121.5m | Q1 2020 included a $110m CARES Act tax benefit |
| Net income attributable to Amneal | $6.7m | $115.1m | Basic/diluted EPS: $0.05/$0.04 vs. $0.78/$0.78 |
| Cash from operating activities | $148.1m | $49.0m | Improved mainly through receivable collections |
| Cash used in investing activities | $12.7m | $262.0m | Prior period included AvKARE-related acquisition spending |
| Cash from (used in) financing activities | ($26.1m) | $468.0m | Prior period included debt and revolver borrowings |
| Cash and cash equivalents | $452.1m | $341.4m at Dec. 31, 2020 | Restricted cash was an additional $3.7m |
| Debt, net of discounts | $2,758.0m | $2,779.5m at Dec. 31, 2020 | Current and long-term debt; excludes lease liabilities and related-party notes |
Current assets were $1,559.7m and current liabilities were $636.8m at March 31, 2021. The company reported $435m of available revolving-credit capacity. It recorded $33.9m of net interest expense for the quarter.
Material changes and segment performance
- Generics: Revenue fell 11% to $312.5m and operating income fell to $68.7m from $81.8m. Lower Oseltamivir sales and elevated returns amid low influenza activity were key factors. New products launched in 2020 and 2021 contributed $36m of revenue growth; management also cited improved gross margin from product mix, lower material costs and plant utilization.
- Specialty: Revenue rose 9% to $95.9m and operating income rose to $15.8m from $9.9m. Growth in Rytary and Unithroid contributed; the company expects Zomig Spray patent exclusivity to end May 29, 2021.
- AvKARE: Revenue was $84.7m versus $58.0m, and operating income was $2.0m versus $0.3m. The 2021 quarter included three months of operations, compared with two months in the 2020 quarter following the January 2020 acquisition.
- Research and development expense increased to $48.2m from $36.4m, including higher licensing and milestone spending and project costs for IPX203 and complex generics. SG&A rose to $90.7m from $78.0m.
Outlook, risks and unusual items
- Management estimated 2021 capital expenditures of $60m–$70m and said available liquidity was expected to support planned operations and obligations for the next 12 months. It did not provide a specific revenue or earnings forecast in the supplied filing text.
- The Kashiv Specialty Pharmaceuticals acquisition closed April 2, 2021, after quarter-end. Amneal paid $70m upfront, expects to pay $30m in January 2022, and may owe up to $8m in regulatory milestone payments plus product royalties. The acquired business develops drug-delivery platforms, 505(b)(2) products and complex generics.
- Debt service remains significant. Management expected 2021 Term Loan principal and interest payments of $41m and $112m, respectively, and Rondo Term Loan principal and interest payments of $9m and $6m.
- COVID-19-related demand and supply disruptions remain uncertain. The filing cites reduced influenza activity and Oseltamivir returns, possible further supply-chain interruptions, and potential effects on customer demand, cash flows and borrowing access.
- Legal and regulatory exposure includes generic-drug pricing antitrust litigation and investigations, opioid litigation, ranitidine and metformin product litigation, and patent disputes. The filing generally does not provide estimable loss ranges for these matters; recorded legal liabilities were $11m at March 31, 2021.
- The three largest customers represented approximately 82% of gross product sales in Q1 2021. The company also disclosed that $206m of potential Tax Receivable Agreement liability was unrecognized because realization of the related tax benefits was not considered more likely than not; future obligations could be larger.
- The company had completed 280 of a planned 300–350 employee reductions under a restructuring program expected to run through 2021. It reported no material changes to its previously disclosed risk factors and stated disclosure controls were effective as of March 31, 2021.
Important facts for investors to verify
- Whether new product launches and Specialty/AvKARE growth can offset ongoing Generic base-business erosion and the unusual Oseltamivir decline.
- The sustainability of operating cash flow, including the effect of receivable collections, inventory needs and customer concentration.
- Debt repayment capacity, borrowing costs, available revolver capacity and any effects from interest-rate or reference-rate changes.
- Post-close accounting, acquired assets and liabilities, and the financial contribution and contingent costs of the Kashiv acquisition.
- Developments, potential outcomes and financial exposure from antitrust, opioid, product-liability and other legal proceedings, which are largely unquantified in the filing.
- Potential recognition and timing of Tax Receivable Agreement payments, and the impact of COVID-19 on supply, demand and planned spending.